Its developer Ri Il Hun, a section chief of the Tumor Institute under the Academy of Medical Science, told KCNA that it had been developed to prevent liver, lung, stomach and other cancers from relapse and metastasis after operation.

According to nearly ten years of animal experiments, its cancer growth suppression rate is as high as 68.8 percent, he said.

The clinical examinations of some 600 patients operated for liver, lung and stomach cancers show that the efficacy of the vaccine is 54, 32.8 and 20.3 percent higher than other medicines in the five-year survival rate, he added.

Ri Yong Il, a 48-year-old man who took the vaccine more than eight years ago after operation for hepatocellular carcinoma (10x9cm), is still in existence.

Ri Ton Sop, a 66-year-old man who took the vaccine nine years ago after undergoing an operation for lung cancer, is still alive without any relapse or metastasis.